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Key questions
What is already known?
 ► Barriers to malaria elimination include mosquitoes 
forming resistance to insecticides used in long- 
lasting insecticidal nets (LLINs) and/or shifting their 
feeding patterns such that they avoid indoor control 
methods.
 ► Ivermectin is a systemic insecticide that has been 
identified as a possible intervention method due to 
its mosquitocidal effect; however, over- reliance on a 
single drug should be avoided to minimise selection 
of resistant targets.
What are the new findings?
 ► A number of systemic insecticides exist that should 
be considered for use in malaria control programmes 
already employing LLINs.
 ► Isoxazolines and spinosyns are predicted to require 
less frequent dosing than avermectins (ie, ivermec-
tin), thus making them operationally realistic choices 
to test for mass drug administration.
What do the new findings imply?
 ► Systematic insecticides besides ivermectin could be 
used in tandem with LLINs to improve vector control 
strategies and reduce the transmission of malaria.
 ► There is a critical need to further investigate these 
drugs’ safety and pharmacokinetics in relevant hosts 
and their effects on mosquitoes
AbsTrACT
background
Long- lasting insecticidal nets and indoor residual sprays 
have significantly reduced the burden of malaria. However, 
several hurdles remain before elimination can be achieved: 
mosquito vectors have developed resistance to public 
health insecticides, including pyrethroids, and have altered 
their biting behaviour to avoid these indoor control tools. 
Systemic insecticides, drugs applied directly to blood hosts 
to kill mosquitoes that take a blood meal, offer a promising 
vector control option. To date, most studies focus on 
repurposing ivermectin, a drug used extensively to treat 
river blindness. There is concern that overdependence on a 
single drug will inevitably repeat past experiences with the 
rapid spread of pyrethroid resistance in malaria vectors. 
Diversifying the arsenal of systemic insecticides used for 
mass drug administration would improve this strategy’s 
sustainability.
Methods
Here, a review was conducted to identify systemic 
insecticide candidates and consolidate their 
pharmacokinetic/pharmacodynamic properties. The 
impact of alternative integrated vector control options 
and different dosing regimens on malaria transmission 
reduction are illustrated through mathematical model 
simulation.
results
The review identified drugs from four classes commonly 
used in livestock and companion animals: avermectins, 
milbemycins, isoxazolines and spinosyns. Simulations 
predicted that isoxazolines and spinosyns are promising 
candidates for mass drug administration, as they 
were predicted to need less frequent application than 
avermectins and milbemycins to maintain mosquitocidal 
blood concentrations.
Conclusions
These findings will provide a guide for investigating and 
applying different systemic insecticides to achieve more 
effective and sustainable control of malaria transmission.
InTroduCTIon
Long- lasting insecticidal nets (LLINs) and 
indoor residual sprays (IRS) have played 
significant roles in reducing the burden of 
malaria.1 2 However, several hurdles remain 
before elimination can be achieved. First, 
pyrethroids are heavily used in LLINs and, 
previously, IRS.3 As a result, the widespread 
and sustained use of this single class of 
insecticides has selected for mosquitoes 
that are resistant to the primary interven-
tion methods.4 5 Second, because LLINs 
and IRS target mosquitoes that feed indoors 
on humans, mosquitoes have shifted their 
feeding patterns to avoid exposure. For 
instance, increasing numbers of mosquitoes 
have been found to seek their blood meals 
and/or rest outdoors after a new deploy-
ment of bed nets.6 Some malaria- transmitting 
mosquitoes avoid indoor interventions by 
obtaining blood meals from animal hosts.7 
Though livestock cannot act as parasite reser-
voirs, bites diverted away from human hosts 
can act as temporary reprieve from insecti-
cide exposure, increasing vector lifespans, 
and consequently, contributing to perpetu-
ated transmission.8
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To build on recent gains in malaria vector control, it 
is critical to develop a method that is effective against 
pyrethroid resistant, outdoor feeding/resting or plas-
tically zoophagic mosquitoes.9 A promising solution is 
systemic insecticides, drugs that render host blood toxic 
to mosquitoes that take a blood meal.10 The types of 
systemic insecticides most relevant to treating mosqui-
toes are ectoparasiticides, drugs that target ectopara-
sites (eg, blood- feeding arthropods) and endectocides, 
drugs that target both endoparasites and ectoparasites. 
Many of these drugs have a mode of action distinct from 
pyrethroids, and thus should be effective against mosqui-
toes regardless of their susceptibility to pyrethroids.11–15 
These systemic insecticides have been widely used to treat 
humans, livestock and domestic animals for infections 
ranging from gastrointestinal and systemic nematodes to 
blood- feeding parasites.16–19
Studies have demonstrated that mass drug adminis-
tration (MDA) of the systemic insecticide ivermectin to 
humans and cattle can significantly decrease mosquito 
population numbers temporarily.20 21 To attain longer 
lasting impacts, the optimal use of systemic insecticides 
requires understanding their pharmacokinetics in the 
host to determine the dosing frequency necessary for 
maintaining lethal blood drug concentrations. Addition-
ally, understanding the mosquito population’s feeding 
patterns will guide the decision of whether humans or 
animal hosts should be targeted. Finally, recent history 
has highlighted the importance of avoiding over- reliance 
on singular control tools; thus, it would be prudent to 
both investigate the effects of combining systemic insec-
ticides with extant interventions and expand the arsenal 
of effective systemic insecticides from the current candi-
date of interest, ivermectin.22 23 Here, a review of systemic 
insecticides was conducted to collate the pharmacokinetic 
properties for different drug–host–route combinations. 
These data were then used to parameterise a mathemat-
ical model to illustrate the projected gains achievable in 
malaria control programmes already employing LLINs.
MeTHods
Patient and public involvement
Patients and the public were not involved.
Literature review
Veterinary and human parasiticides were identified with 
systemic properties that affected arthropods and were 
not prohibited nor being phased out of use in most coun-
tries. These included avermectins, milbemycins, neonic-
otinoids, spinosyns and isoxazolines. Unlike pyrethroids, 
which target voltage- gated sodium channels, avermectins 
and milbemycins target glutamate- gated chloride chan-
nels, neonicotinoids and spinosyns target unique sites 
of the nicotinic acetylcholinesterase receptor, and isox-
azolines target γ-aminobutyric acid- gated chloride chan-
nels.11–15 Further discussion of the parasiticides’ struc-
tures and modes of action may be reviewed elsewhere.12–15
To determine the relevant pharmacokinetic studies 
for different systemic insecticide treatments, a review 
of the electronic literature was conducted. PubMed 
was searched from inception to 24 July 2018 using the 
following search terms: (“systemic insecticide” OR 
endectocide OR ectoparasiticide OR avermectin OR 
abamectin OR doramectin OR eprinomectin OR iver-
mectin OR selamectin OR milbemycin OR “milbemycin 
oxime” OR moxidectin OR isoxazolines OR afoxolaner 
OR fluralaner OR sarolaner OR lotilaner OR neonico-
tinoids OR imidacloprid OR nitenpyram OR spinosyns 
OR spinosad OR spinetoram OR “N- tert- butyl nodulispo-
ramide”) AND (pharmacokinetics OR “area under the 
curve” OR kinetics OR “half- life” OR Cmax OR Tmax) 
AND (blood OR plasma). The complete list of accepted 
and rejected studies is available on request to the corre-
sponding author.
Study inclusion was determined in two steps. First, the 
titles and abstracts were screened to determine studies 
that were irrelevant, not primary research (eg, letter or 
review), or purely computational. Irrelevant studies were 
defined as those focusing on drug mechanism, a drug 
that was not systemic or ineffective against mosquitoes, or 
hosts that are not targeted by mosquitoes for blood meals. 
After the initial screen, the full papers of the remaining 
studies were reviewed. Inclusion required the reporting 
of relevant pharmacokinetic parameters in plasma, use 
of a standardised drug, application of a single drug, and 
a test- population size n>3.
From the selected studies, the following data were 
extracted directly into an Excel spreadsheet: host studied, 
drug applied, dose applied, administration route, 
maximum drug concentration reached in the plasma 
(Cmax), area under the curve, absorption and elimination 
half- lives, mean residual time and volume of distribution. 
All data were summarised using basic descriptive statistics 
(mean and SD or SE) for each drug–host–route scenario. 
As different classes of drugs require different concentra-
tions to achieve the same toxicity level, the doses for each 
combination of drug–host–route were not compared. 
Instead, the analysis focused on the pharmacokinetic 
metrics that impact the treatment’s efficacy and can be 
used to calculate the appropriate dose.
data analysis
To determine the underlying trends between the phar-
macokinetic parameters and each categorical factor 
(drug, host, administration route), a weighted (using 
the inverse of the variance) three- way analysis of variance 
(ANOVA) was conducted in Stata. Hosts with fewer than 
10 observations were grouped into two categories based 
on bodyweight: other small (<75 kg) and other large 
(>75 kg).
Model development
To investigate strategies for applying different systemic 
insecticides to further limit malaria transmission, models 
from the literature were modified24–26 (see online 
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Table 1 Range of pharmacokinetic and pharmacodynamic parameters collected from the literature review (see online 
supplementary table 1 for more detail)
Cmax
(ng/mL)
Half- life
(day-1)
F50
(ng/mL)
LC50D(TD)
(ng/mL)
TD
(days)
Macrocyclic lactones
  Doramectin 3.8:139.8 2.5:11.1 9.2 30.6 9
  Eprinomectin 3.4:503.0 1.0:5.7 1.0 7.6 9
  Ivermectin 2.7:316.0 0.4:7.8 4.1 7.3 9
  Moxidectin 2.6:420.0 1.4:23.1 478.4 1178.0 9
Isoxazolines
  Afoxolaner 621.9:1107.0 14.8:15.6 0* 66.8 1
  Fluralaner 513.3:7109.0 11.0:18.6 0* 21.2 1
Spinosyns
  Spinosad 1550.0 11.3 0* 461.0 5
* F50  remains to be measured for Anopheles.
supplementary text and table 1 for model development 
and parameter values). The proportion of bites that lead 
to infection, egg- laying rate and death rate of mosquitoes 
depend on the concentration of insecticide in LLINs (N) 
and systemic insecticides in livestock or humans (DL or 
DH, respectively) to which a mosquito is exposed.
27–30 The 
model assumes the effects of the LLINs and systematic 
insecticides are additive and independent of each other’s 
concentration. Different host species and administration 
routes are characterised by different rates of adsorp-
tion, which were often not reported. Hence, to allow for 
comparison, the model represented the systemic insec-
ticide’s pharmacokinetics as a single compartment and 
the initial insecticide concentration as the reported Cmax.
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(7)
The impact of insecticides used for livestock, human and 
bed net treatment diminishes as they degrade at rates  kDL
 ,  kDH   and  kN . These rates were determined by the half- lives 
recorded from the review. The transmission potential 
from vector to human or vice versa (bh and bm, respec-
tively) is a function of biting frequency (a), the propor-
tion of bites that successfully leads to infection in humans 
or mosquitoes (b and c, respectively), the coverage of bed 
nets (CN) and whether the LLIN’s insecticidal concen-
tration is above the lethal concentration for killing 50% 
of the population in a set amount of time ( LC50N
[
TN
]
 ). 
Mosquitoes lay eggs at a rate of  βm , but this can be modi-
fied with the introduction of certain systemic insecticides 
( βmc ). Similarly, the mosquito natural death rate (μm) is 
modified with the introduction of LLINs and systemic 
insecticides ( µmc ). For both the egg laying and death 
rates, the impact of different control strategies depends 
on the proportion of bites on humans ( pH ), the coverage 
of LLINs and systemic insecticides in livestock or humans 
(CN, CL, CH, respectively), and the respective concentra-
tion thresholds for reducing fecundity or survival by 50% 
( F50, LC50N
[
TN
]
 , and  LC50D[TD] ).
The relationship between mosquito fecundity or 
mortality and the concentration of LLINs or systemic 
insecticides is not linear, but is captured by Hill kinetics. 
The  F50 ,  LC50D
[
TD
]
 , and Hill coefficients ( Hb  and  Hd  for 
egg- laying and death rates, respectively) were calculated 
for lab- reared Anopheles for different systemic insec-
ticides by fitting a Hill equation to published data28–30 
(online supplementary figures 1 and 2). The  LC50N
[
TN
]
  
was calculated for wild Anopheles that displayed a range 
of resistance to LLINs, and the Hill coefficient ( Hn ) 
was calculated for laboratory reared, permethrin resis-
tant Anopheles by fitting a Hill equation to published 
data.27 31 The time window ( TN or TD ) associated with 
each insecticide’s  LC50  was based on previously reported 
measurements.27–30
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Figure 1 Identification of existing applications for systemic insecticides. (A) A review of PubMed identified relevant studies 
of existing systemic insecticides. (B–D) The included studies covered a range of different hosts, systemic insecticides and 
administration routes.
simulations
This model was used to explore the impact of combining 
different systemic insecticide treatments and LLINs on 
permethrin- resistant mosquitoes. A new LLIN was intro-
duced every 3 years, as recommended by the WHO.32 
Systemic insecticide treatments were designed to test 
a range of half- lives (0.1:100 days), dose concentra-
tions (1:105 ng/mL), F50s (0:480 ng/mL) and  LC50D
[
TD
]
 s 
(7:1180 ng/mL), based on data mined from the review. 
The simulation begins with the initial concentration 
of drug in the host’s blood, approximated by Cmax. The 
appropriate dose necessary to achieve Cmax can be calcu-
lated based on pharmacokinetics associated with each 
host species, as previously documented.33 Although 
many of the systemic insecticides identified in the review 
remain to be characterised as mosquitocidal candi-
dates,  LC50D
[
TD
]
s  were identified from the avermectin, 
moxidectin, isoxazoline and spinosyn classes for Anoph-
eles gambiae or Anopheles arabiensis and used to establish 
a range of realistic values.  F50s  were only reported for a 
subset of avermectins and moxidectin. Each treatment 
characterised by half- life, Cmax,  F50 , and  LC50D
[
TD
]
  was 
dosed at frequencies ranging from weekly to annually. 
Strategy outcome was quantified by calculating the rela-
tive reduction in malaria prevalence after 3 years of drug 
treatment and LLIN coverage ( MN+D ) relative to 3 years of 
LLINs alone ( MN ).
 Relative reduction =
MN−MN+D
MN
× 100 (8)
This framework was applied to evaluate strategies for 
areas with different levels of baseline malaria, mosquito 
populations with different feeding behaviours and 
different host coverage scenarios.
The livestock and human host coverage necessary to 
achieve a minimum 10% relative reduction in malaria 
for different dosing frequencies was estimated for each 
drug by holding the Cmax and half- life constant (online 
supplementary table 2). When available, the livestock 
values were based on topically or orally treated cattle 
and the human parameters were based on topically or 
orally treated ‘(other) small’ (the category humans were 
grouped into, due to small sample size). The exception 
is ivermectin, where the human host parameters were 
based on the weighted averages from studies of humans 
orally treated with ivermectin (Cmax=40.7 ng/mL, half- 
life=3.4 days). For drugs that were only characterised in 
dogs and small animals, those parameters were used for 
both human and livestock parameters.
resuLTs
data retrieval
From the initial 375 articles returned by the search, 237 
full- text articles were assessed for eligibility, and 139 met 
the eligibility criteria (figure 1A). The studies reported 
pharmacokinetic parameters in 8 different host catego-
ries, 10 systemic insecticides and 6 administration routes 
(figure 1B–D). The three most studied hosts were cattle, 
sheep and dogs. Systemic insecticides studied included 
five avermectins (abamectin, doramectin, eprinomectin, 
ivermectin and selamectin), three isoxazolines (afox-
olaner, fluralaner and lotilaner), one milbemycin 
(moxidectin) and one spinosyn (spinosad). These insecti-
cides were applied intramuscularly, intraruminally, intra-
venously, orally, subcutaneously or topically. Note that 
intraruminal and intravenous routes are experimental 
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Figure 2 Half- life and Cmax are dependent on interactions 
between drug class, host and administration route. (A) Half- 
life is affected by the interaction between administration 
route and drug class. (B) The three most studied hosts 
show the effect of host and drug class on drug half- life. 
(C) The interaction between drug application route and 
host affects the drug half- life. (D) Cmax is affected by the 
interaction between host and drug. (E) The interaction 
between administration route and host also impacts Cmax. 
Drug classes: A, avermectin; I, isoxazoline; M,milbemycin; 
S,spinosyn; Routes: Im,intramuscular; Ir,intraruminal; 
Iv,intravenous; O,oral; S,subcutaneous; T, topical.
and not currently operationally feasible; however, they 
were included to help determine the full range of action 
possible for each drug.
data analysis
To evaluate the different treatment scenarios, weighted 
three- way ANOVAs were conducted for each pharma-
cokinetic parameter. Elimination half- life and Cmax 
were the only parameters with significant interactions 
(p<0.05) with host, route and drug. The significant effec-
tors of half- life were drug class (p=0.016), route of admis-
sion (p=0.007), and interactions between host and route 
(p<0.001) and drug and route (p=0.007). Regardless of 
route of administration, the order of drugs from shortest 
to longest half- lives was avermectins<milbemycins<spino-
syns<isoxazolines. The median half- life for avermectins 
and milbemycins was <10 days for all routes of admin-
istration, whereas isoxazolines’ half- life was >10 days 
(figure 2A, online supplementary figure 3). Comparing 
median half- lives for a given drug class across hosts showed 
some host dependency. For instance, milbemycins had a 
longer median half- life in dogs (19.4 days) than in other 
hosts (<10 days) and avermectins had a longer median 
half- life in cattle than in other hosts (figure 2B, online 
supplementary figure 4). When comparing administra-
tion routes across different hosts, topically applied drugs 
typically achieved longer half- lives than orally applied 
ones (figure 2C, online supplementary figure 5).
The significant factors for Cmax were drug (p=0.03) and 
interactions between host and drug (p=0.002) and host 
and route (p<0.001). The order of drugs from lowest to 
highest Cmax was different from that of half- lives: milbe-
mycins<avermectins<isoxazolines<spinosyns (online 
supplementary figure 6). Cattle reported the lowest 
median Cmax for milbemycins, whereas dogs and sheep 
had the lowest Cmax for avermectins (figure 2D, online 
supplementary figure 7). There was also a dependency 
of Cmax on host and route (figure 2E, online supplemen-
tary figure 8). Although the intravenous route resulted 
in the highest Cmax for different hosts, due to the drug 
being directly delivered into the bloodstream, the order 
of resulting Cmax for other routes varied based on host.
The spread in half- lives and Cmaxs seen for a given drug–
host–route combination can be attributed to host factors 
that may affect drug absorption and, consequently, the 
plasma concentration. These factors include age, gender, 
breed, diet, parasite infection, pregnancy, lactation, 
and whether topically treated hosts are restricted from 
self- licking.34–41 Understanding how host conditions 
affect basic pharmacokinetics is critical for designing 
optimal treatment strategies that can account for natural 
variations.
basic dynamics of malaria transmission and control methods
The model captures the temporal dynamics of malaria 
transmission in a human population exposed to mosqui-
toes that bite humans and livestock indiscriminately. 
On the LLIN introduction, a general decline in malaria 
prevalence (symptomatic and asymptomatic individuals 
combined) is observed, followed by a steady increase as 
the insecticide in the net degrades and fewer mosquitoes 
are killed by LLIN exposure (figure 3A). The addition of 
treating one blood host population with systemic insecti-
cide can further reduce malaria prevalence when applied 
at sufficient frequency.
dosing strategy design and evaluation
To quantify the efficacy of different dosing strategies, the 
relative reduction in malaria prevalence after 3 years of 
using LLINs and applying systemic insecticides to one 
blood host population was compared with that of using 
LLINs alone. For a set dosing frequency, the relative 
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Figure 3 Modelling malaria transmission and control 
methods. (A) The malaria prevalence ratio is compared 
for a population using LLINs alone (MN, black), LLINs with 
livestock treated yearly with systemic insecticide (MN+D1, 
red) and LLINs with livestock treated monthly with systemic 
insecticide (MN+D12, blue). (B) For a strategy using LLINs 
and livestock treated at a set dosing frequency (here, 
monthly), the relative reduction in malaria prevalence can be 
calculated for insecticides of various half- lives and Cmaxs. 
(C–I) The dosing frequency necessary to achieve a 10% 
relative reduction in malaria prevalence can be calculated 
for insecticides with different pharmacokinetic properties. 
Overlaying pharmacokinetic values gathered from the 
review predicts the minimum dosing frequency of existing 
systemic insecticides in certain host–route scenarios. 
Contour definitions from left to right: weekly, monthly, 
quarter- annually, biannually, annually. Here, we assume 
indiscriminate biting behaviour (ph=0.5). LLINs, long- lasting 
insecticidal nets.
reduction increased as a function of half- life and Cmax 
(figure 3B).
The minimum dosing frequency was calculated to 
achieve a target relative reduction (here, 10%) for 
different drugs distinguished by half- life, Cmax,  F50 , and 
 LC50D
[
TD
]
  (figure 3C–I). The drugs with the longest half- 
lives and highest Cmaxs needed to be dosed the least often 
to maintain a sufficiently high concentration to remain 
lethal to feeding mosquitoes. Given the same half- life and 
Cmax, drugs with higher  F50 and LC50D
[
TD
]
  needed to be 
dosed more frequently to compensate for the decreased 
efficacy of drug on mosquito fecundity or survival.
Overlaying the data gathered in the review for drugs 
with reported  F50  s and  LC50D
[
TD
]
s  for Anopheles gambiae 
sensu lato predicted the frequency at which these existing 
drugs would need to be applied to achieve a 10% relative 
reduction in malaria prevalence. The avermectins, repre-
sented by ivermectin, eprinomectin and doramectin, 
have relatively low  F50  s and  LC50D
[
TD
]
  s, suggesting that 
relatively low concentrations of drug in the bloodstream 
would affect the fecundity and death rates of feeding 
mosquitoes. However, this impact is limited by these 
drugs’ relatively short half- lives, ranging from 0.4 to 11.1 
days (table 1). Depending on the host and administration 
route, regimens with dosing frequencies ranging from 
weekly to quarter- annually would be required to achieve 
a 10% relative reduction in malaria prevalence. Although 
ivermectin and eprinomectin have a similar  LC50D
[
TD
]
 , ivermectin has a stronger effect on fecundity (online 
supplementary figure 2). Consequently, ivermectin 
would require less frequent dosing than eprinomectin 
to achieve the same target reduction. Doramectin has a 
lower impact on fecundity and death rates, with a higher 
 F50  and  LC50D
[
TD
]
  than ivermectin and eprinomectin.
Although fluralaner and afoxolaner have higher 
 LC50D
[
TD
]
s  than ivermectin, they were predicted to 
achieve 10% relative reduction with yearly dosing, due to 
their longer half- life and higher Cmax. Similarly, spinosad 
has a high  LC50D
[
TD
]
 , a relatively long half- life of 11.3 
days, a higher Cmax of 1550.0 ng/mL, and could achieve 
a 10% relative reduction when dosed biannually. These 
results are conservative, as the effect of fluralaner, afoxol-
aner, and spinosad on fecundity was assumed to be zero 
until it has been characterised in mosquitoes.
Despite some of the moxidectin studies reporting 
relatively long half- lives and high Cmaxs, its high  F50  and 
 LC50D
[
TD
]
  mean that it would have to be dosed more 
frequently (>weekly) or at higher doses to provide an 
effective complement to LLINs.
Application to different scenarios
This framework can predict the extent to which systemic 
insecticides could aid in the reduction of malaria prev-
alence in scenarios with different endemicities (online 
supplementary figure 9a–c). For instance, in a low- level 
mesoendemic environment (malaria prevalence=25%),42 
LLINs alone played a significant role in reducing trans-
mission; however, additional treatment of livestock and 
humans further reduced prevalence and could theoret-
ically break transmission. In a high- level mesoendemic 
environment (malaria prevalence=50%), LLINs alone 
were not as effective and the additional treatment of 
livestock and humans could significantly reduce malaria 
transmission. When malaria is hyperendemic (preva-
lence=65%), the addition of systemic insecticide treat-
ment reduced malaria prevalence relative to LLINs alone; 
however, to bring malaria transmission under control, 
longer, sustained treatment and/or the use of drugs with 
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Figure 4 Effect of different coverage proportions in two 
hosts on the reduction in malaria prevalence after 3 years 
of treatment. (A–F) For each drug, the dosing frequency 
necessary to achieve at least a 10% relative reduction (RR) 
in malaria prevalence was calculated for a range of livestock 
and human coverages. The contour lines represent the 
minimum dosing frequency necessary to achieve the target 
reduction threshold. The colourmap indicates the level of 
relative reduction in malaria prevalence for a given coverage 
and dosing frequency. Here, we assume indiscriminate biting 
behaviour (ph=0.5).
longer half- lives and higher Cmax, such as the isoxazolines, 
would be necessary.
Similarly, this framework can help evaluate control 
strategies for mosquitoes with different blood meal pref-
erences (online supplementary figure 9d–e).43 Malaria 
transmission in regions with zoophilic mosquitoes was 
largely controlled by LLINs because the mosquitoes 
do not target humans as frequently. Treating livestock 
with systemic insecticides would be more effective than 
treating humans, requiring less frequent dosing for a 
drug with a given half- life and Cmax. Malaria in regions with 
anthropophilic mosquitoes was reduced the most with 
the treatment of both livestock and humans, with most 
of the reduction due to the treatment of humans. Dosing 
frequencies were increased, given the need to maintain 
high enough lethal systemic insecticide concentrations to 
affect a greater number of mosquitoes targeting humans 
for blood meals.
estimating coverage
While 100% coverage is ideal, it is difficult and often 
unrealistic to achieve in practice. The minimum dosing 
frequency of each drug was calculated to achieve a rela-
tive reduction >10% for a range of humans and livestock 
coverage (figure 4). Intuitively, as the coverage of both 
hosts increased, the dosing frequency necessary to reach 
the target reduction generally decreased. Ivermectin 
treatment of human and cattle appeared to contribute 
equally to malaria reduction (figure 4A). If at least 50% 
of both humans and cattle were treated with ivermectin 
every 2 months, then at least a 15% relative reduction in 
malaria could be achieved over 3 years. If 75% of both 
humans and livestock were treated, then the dosing 
frequency could be reduced to once every 4 months and 
still achieve a 10%–12% relative reduction.
Eprinomectin appeared less effective at reducing 
malaria than ivermectin, with the lowest frequency 
dosing option being every 2 months (figure 4B). This is 
largely due to ivermectin’s greater impact on fecundity 
(online supplementary figure 2). Assuming that the 
pharmacokinetic properties of eprinomectin in ‘small’ 
hosts are a proxy of those in humans, the malaria preva-
lence was more sensitive to increasing the eprinomectin 
coverage of humans than of livestock. This is because 
the eprinomectin reached a higher Cmax in humans 
than cattle (20.1 vs 11.0 ng/mL, respectively) and had a 
slightly longer half- life in humans than in livestock (4.8 vs 
3.5 days) (online supplementary table 2). Thus, human 
blood meals would remain toxic to a mosquito for a 
longer period of time and could remain effective at lower 
dosing frequencies.
Doramectin was the least effective of the avermectins, 
requiring weekly dosing for the majority of the coverage 
scenarios to result in a 10% relative reduction in malaria 
prevalence (figure 4C). This is reflective of its  LC50D
[
TD
]
  
being larger than the Cmax.
Assuming that the pharmacokinetic properties of both 
isoxazolines in dogs and ‘small’ hosts are a proxy of those 
in humans and cattle, fluralaner and afoxolaner were 
predicted to achieve the 10% reduction with yearly dosing 
and very low coverage (20% for fluralaner and 30% for 
afoxolaner) (figure 4D–E). With 70%–80% coverage of 
both populations, fluralaner was predicted to reduce 
malaria prevalence by 50%. However, afoxolaner applied 
at the same coverage would only reduce malaria prev-
alence by 25% because of its lower Cmax and higher 
 LC50D
[
TD
]
 , relative to fluralaner. The isoxazolines’ Cmax is 
one to two orders of magnitude greater than the aver-
mectins’, which results in the drug remaining at toxic 
levels in the blood for longer periods of time.
Assuming that spinosad’s pharmacokinetic prop-
erties in dogs can serve as a proxy for those in live-
stock and humans, it was also predicted to require less 
frequent dosing at lower coverage than the avermectins 
(figure 4F). Although spinosad had one of the highest 
Cmax values of the drugs simulated here, it also had one of 
the highest  LC50D
[
TD
]
 s. Thus, for a given coverage level, 
spinosad needed to be dosed more frequently than isox-
azolines to reach the target reduction level.
Moxidectin was not capable of reducing malaria prev-
alence, regardless of dosing frequency or host coverage, 
because its  LC50D
[
TD
]
  is three orders of magnitude greater 
than its Cmax.
dIsCussIon
To date, ivermectin has been the main systemic insec-
ticide considered for its mosquitocidal properties 
and, until recently, the only one marketed for human 
use.44–46 However, there are additional avermectins and 
different drug classes, such as milbemycins, spinosyns 
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and isoxazolines, that should be screened as potential 
candidates for future mosquito control methods in live-
stock and/or humans. Here, through the combination of 
a review and a malaria transmission model, it was demon-
strated how existing systemic insecticides can be applied 
to reduce malaria transmission in a range of scenarios. 
To make a 10% reduction in malaria prevalence beyond 
what is achieved by LLINs, some of the identified drugs 
need to be applied at frequencies much higher than the 
current MDA’s annual or biannual dosing regimen and 
at very high coverages.19 For instance, it was estimated 
that moxidectin would need to be dosed at an unreal-
istic frequency, more than once a week, to reduce malaria 
transmission. This supports studies that show moxidectin 
has little impact on mosquitoes and would unlikely be an 
effective choice for mosquito population control.28 Alter-
natively, isoxazoline, afoxolaner and spinosad are esti-
mated to reduce malaria prevalence when applied once 
or twice a year with as little as 20%–30% (isoxazolines) or 
60% coverage (spinosad).
The likelihood of these non- ivermectin drugs being 
administered to humans to improve vector control 
depends on their safety profiles as well as the regulatory 
and operational contingencies of conducting repeated 
MDAs. Moxidectin was approved in 2018 by the Food and 
Drug Administration to treat humans for onchocerci-
asis47; however, based on the above predictions, the dosing 
frequency necessary for moxidectin to make blood meals 
toxic to mosquitoes would be too high for an operation-
ally feasible MDA. While isoxazolines remain to be tested 
in humans, Miglianico et al’s preliminary assessment of 
their safety anticipates that the prescribed human doses 
would be comparable to or lower than the concentrations 
reported to have no adverse effects in rats and dogs.30 It 
should be noted that, while isoxazolines are well toler-
ated by many cats and dogs, there have been instances 
of adverse events.48 49 Understanding individual- level risk 
factors for adverse effects will be important when charac-
terising these drugs in new hosts and determining who to 
treat in MDAs. Based on the decades of repeated MDA 
of ivermectin in a range of settings, a biannual treat-
ment strategy to improve vector control should be oper-
ationally feasible and could possibly be coordinated with 
existing campaigns.19
To reduce the dosing frequency of ivermectin and other 
drugs with relatively short half- lives, there are methods to 
attain higher concentrations of drug for longer periods 
of time. Recently, a study demonstrated the tolerability 
of high doses of ivermectin in humans and the resulting 
increase in time that the blood was lethal to mosquitoes.50 
As an alternative to increasing the concentration of the 
delivered dose, there are adjuvants reported to improve 
the absorption or extend the half- life of systemic insecti-
cides, such as lipids for lipophilic drugs or inhibitors for 
efflux pumps that remove xenobiotics, respectively.51–57 A 
third promising solution is the development of sustained- 
release devices, which have been shown to maintain a 
target concentration for 280 days in livestock.58
When designing an MDA to effectively reduce the 
transmission of a vectorborne disease, the secondary 
effects should also be considered.
emergence of resistance
As the frequency of insecticide administration is 
increased to break the malaria transmission cycle, it is 
imperative to consider how these new treatment regi-
mens will contribute to the emergence of resistance in 
mosquitoes and other parasites. Resistance is considered 
the greatest threat to malaria vector control.59 The two 
main mechanisms of insecticide resistance observed so 
far in mosquitoes can be categorised as metabolic or 
target site mutations.60 Studying how other arthropods 
have formed resistance to systemic insecticides will shed 
light on the potential pathways to resistance formation in 
mosquitoes. For instance, macrocyclic lactone resistance 
has been shown to arise in cattle ticks, fruit flies and body 
lice due to increased expression of adenosine triphos-
phate (ATP)- binding cassette transporter, P- glycoprotein 
and P450 genes.61–63 With strategic use of systemic insec-
ticides that target different mechanisms, monotherapy 
could be avoided and the development of resistance in 
mosquitoes could be delayed.
Selecting for resistant, non- mosquito parasites is also 
a concern. One study reported ivermectin- resistant 
Rhipicephalus microplus found on 50% of cattle being 
treated regularly with ivermectin for gastrointestinal 
nematodes.64 Similarly, repeated treatment of ivermectin 
for onchocerciasis in humans has selected for resistant 
Onchocerca volvulus in Ghana.65 As these systemic insecti-
cides are commonly used to control other parasite infec-
tions in humans and livestock, it is important to consider 
this in drug selection and actively screen for unintended 
consequences. Refugia, or leaving a small portion of 
the population untreated, offers a possible solution for 
reducing the selective pressure on parasites and arthro-
pods to form resistance.64 66
Presence in food products
Considering how different systemic drugs are eliminated 
from a host’s system is also important in evaluating a 
new treatment programme. For instance, lactating hosts 
treated with a single dose of eprinomectin or ivermectin 
produced milk with detectable drug levels for weeks, thus 
exposing the nursing young.67 68 Due to the unknown 
effects of the drug on a newborn, nursing human mothers 
in the first week after delivery have been excluded from 
MDAs of ivermectin.69
Additionally, systemic insecticides from treated hosts 
becomes incorporated into dairy and meat products.70 
Regulations have been established for levels of acceptable 
residues of a few drugs, such as eprinomectin; yet, most 
other drugs have not been licensed for use in dairy animals 
and do not have an acceptable limit for drug concentra-
tion found in milk.71 It was surmised that the extent of 
drug excretion and residence time in milk depends on 
a drug’s lipophilicity and route of administration.72 73 
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However, more studies are needed to characterise the 
different drugs’ excretion in milk and, subsequently, 
establish safety limits for suckling young or consumable 
items. In the meantime, refugia offers a possible solution 
to ensure that the meat and milk produced by a portion 
of the livestock are safe to consume.
Limitations
Since the model parameters were limited to the phar-
macokinetic/pharmacodynamic values reported in 
the literature, there are a number of limitations to this 
approach. To achieve a large enough sample size, hosts 
were categorised by species. As a result, the impact 
of subspecies details, such as breed and health status, 
on pharmacokinetic properties were no longer distin-
guished. For instance, ivermectin was observed to be less 
available in zebu Gobra, a Western African cattle breed, 
than other cattle breeds74; however, the pharmacokinetic 
behaviour of doramectin and moxidectin were similar.75 
Additionally, parasitised animals were reported to have 
faster absorption times and shorter circulation times for 
ivermectin than their healthy counterparts.38 Another 
constraint was being limited to pharmacokinetic data 
from one species as a proxy for how the drug might act in 
cattle or humans. Although interspecies variation in drug 
pharmacokinetics is significant, this was the most rele-
vant data available for simulations until further studies 
are conducted. Furthermore, the effect of the isoxazo-
lines and spinosyns on mosquito fecundity remains to be 
quantified. The proposed model conservatively assumed 
that those drugs had no effect on egg- laying rates. Finally, 
although lotilaner was identified as an isoxazoline with 
a particularly long half- life and high Cmax, its mosquito-
cidal effects remain to be measured and thus could not 
be included in the simulations. These limitations reveal 
the need to further investigate these drugs’ safety and 
pharmacokinetics in relevant hosts and their effects on 
mosquitoes. Nevertheless, this framework can help iden-
tify scenarios in which systemic insecticides should be 
considered for malaria control and develop an effective 
MDA strategy for a range of systemic insecticides.
ConCLusIons
Studies have demonstrated that systemic insecticides can 
significantly decrease mosquito population numbers 
temporarily. To design effective, long- term vector control 
strategies with systemic insecticides, their pharmacoki-
netics and pharmacodynamics need to be understood. 
Here, multiple systemic insecticides with different mech-
anisms of action and pharmacokinetic/pharmacody-
namic characteristics that could be used in MDAs have 
been highlighted. The simulations provide a foundation 
for further characterising how wild mosquitoes respond 
to systemic insecticides. Given the history of mosquitoes 
forming resistance to the insecticides in LLINs and IRS, 
having a variety of systemic insecticide strategies that 
target different mechanisms is key to maximise sustaina-
bility of these promising, new methods.
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